登革热的复杂性:发病机制、临床特征和管理策略。

Discoveries (Craiova, Romania) Pub Date : 2024-06-30 eCollection Date: 2024-04-01 DOI:10.15190/d.2024.8
Maheen Nasir, Javeria Irfan, Aimen Binte Asif, Qudsia Umaira Khan, Haleema Anwar
{"title":"登革热的复杂性:发病机制、临床特征和管理策略。","authors":"Maheen Nasir, Javeria Irfan, Aimen Binte Asif, Qudsia Umaira Khan, Haleema Anwar","doi":"10.15190/d.2024.8","DOIUrl":null,"url":null,"abstract":"<p><p>Dengue fever, transmitted through the bite of infected Aedes mosquitos, poses a significant global threat, particularly in the tropical and subtropical region. In this review, we aim to summarize the existent literature on dengue virus infection and to enlighten the reader on recent advances and knowledge. Dengue virus infection can cause a spectrum of clinical manifestations, ranging from asymptomatic or mild illness to more severe and potentially life-threatening complications. Pathogenesis of dengue is based on viral and host factors. Viral factors include NS1 antigen and genomic factors. Host factors include antibody dependent enhancement, anti-NS1 antibodies, cytokines, cross reactive T-Cell response, HLA allele variation and non-HLA mediated polymorphisms. The clinical picture of dengue is described on the basis of WHO 1997 and 2009 criteria. It is classified into dengue fever, dengue hemorrhagic fever (DHF), and dengue shock syndrome (DSS). Life-threatening complications can develop in severe cases, and this includes renal complications such as acute kidney injury (AKI) and hepatic complications such as hepatic dysfunction and in rare cases, fulminant hepatic failure. Neurological complications, cardiac complications and respiratory distress syndrome have also been reported. Treatment methods include targeting the dengue vector and Carica papaya, a natural remedy with antiviral properties. Additionally, the role of corticosteroids, intravenous immunoglobulins, and mast cell inhibitors has been explored in dengue treatment, aiming to reduce severity. Novel approaches involve drugs targeting dengue proteins and host factors necessary for the virus's life cycle, offering potential avenues for more targeted therapeutic interventions. In recent years, significant progress has been made in the development of vaccines against dengue, with Sanofi Pasteur's Dengvaxia being the first licensed vaccine approved for use. Utilizing various approaches such as recombinant proteins, viral vectors and viral like particles, various alternatives have been provided which aim to be safer substitutes to Dengvaxia while maintaining the effectiveness. A review on dengue is essential for clinicians and healthcare professionals to stay updated on diagnostics, treatment protocols and prevention strategies.</p>","PeriodicalId":72829,"journal":{"name":"Discoveries (Craiova, Romania)","volume":"12 2","pages":"e189"},"PeriodicalIF":0.0000,"publicationDate":"2024-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11910338/pdf/","citationCount":"0","resultStr":"{\"title\":\"Complexities of Dengue Fever: Pathogenesis, Clinical Features and Management Strategies.\",\"authors\":\"Maheen Nasir, Javeria Irfan, Aimen Binte Asif, Qudsia Umaira Khan, Haleema Anwar\",\"doi\":\"10.15190/d.2024.8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Dengue fever, transmitted through the bite of infected Aedes mosquitos, poses a significant global threat, particularly in the tropical and subtropical region. In this review, we aim to summarize the existent literature on dengue virus infection and to enlighten the reader on recent advances and knowledge. Dengue virus infection can cause a spectrum of clinical manifestations, ranging from asymptomatic or mild illness to more severe and potentially life-threatening complications. Pathogenesis of dengue is based on viral and host factors. Viral factors include NS1 antigen and genomic factors. Host factors include antibody dependent enhancement, anti-NS1 antibodies, cytokines, cross reactive T-Cell response, HLA allele variation and non-HLA mediated polymorphisms. The clinical picture of dengue is described on the basis of WHO 1997 and 2009 criteria. It is classified into dengue fever, dengue hemorrhagic fever (DHF), and dengue shock syndrome (DSS). Life-threatening complications can develop in severe cases, and this includes renal complications such as acute kidney injury (AKI) and hepatic complications such as hepatic dysfunction and in rare cases, fulminant hepatic failure. Neurological complications, cardiac complications and respiratory distress syndrome have also been reported. Treatment methods include targeting the dengue vector and Carica papaya, a natural remedy with antiviral properties. Additionally, the role of corticosteroids, intravenous immunoglobulins, and mast cell inhibitors has been explored in dengue treatment, aiming to reduce severity. Novel approaches involve drugs targeting dengue proteins and host factors necessary for the virus's life cycle, offering potential avenues for more targeted therapeutic interventions. In recent years, significant progress has been made in the development of vaccines against dengue, with Sanofi Pasteur's Dengvaxia being the first licensed vaccine approved for use. Utilizing various approaches such as recombinant proteins, viral vectors and viral like particles, various alternatives have been provided which aim to be safer substitutes to Dengvaxia while maintaining the effectiveness. A review on dengue is essential for clinicians and healthcare professionals to stay updated on diagnostics, treatment protocols and prevention strategies.</p>\",\"PeriodicalId\":72829,\"journal\":{\"name\":\"Discoveries (Craiova, Romania)\",\"volume\":\"12 2\",\"pages\":\"e189\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-06-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11910338/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Discoveries (Craiova, Romania)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15190/d.2024.8\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/4/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Discoveries (Craiova, Romania)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15190/d.2024.8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/4/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

登革热通过受感染的伊蚊叮咬传播,对全球构成重大威胁,特别是在热带和亚热带地区。在这篇综述中,我们旨在总结现有的关于登革热病毒感染的文献,并启发读者对最近的进展和知识。登革热病毒感染可引起一系列临床表现,从无症状或轻微疾病到更严重和可能危及生命的并发症。登革热的发病机制是基于病毒和宿主因素。病毒因子包括NS1抗原和基因组因子。宿主因子包括抗体依赖性增强、抗ns1抗体、细胞因子、交叉反应性t细胞反应、HLA等位基因变异和非HLA介导的多态性。登革热的临床情况是根据世卫组织1997年和2009年的标准描述的。登革热分为登革热、登革出血热(DHF)和登革休克综合征(DSS)。严重的情况下可发生危及生命的并发症,包括肾并发症,如急性肾损伤(AKI)和肝脏并发症,如肝功能障碍,在极少数情况下,暴发性肝衰竭。神经系统并发症、心脏并发症和呼吸窘迫综合征也有报道。治疗方法包括针对登革热媒介和番木瓜,一种具有抗病毒特性的天然药物。此外,皮质类固醇、静脉注射免疫球蛋白和肥大细胞抑制剂在登革热治疗中的作用已被探索,旨在降低严重程度。新的方法包括针对登革热病毒生命周期所必需的登革热蛋白和宿主因子的药物,为更有针对性的治疗干预提供了潜在的途径。近年来,在开发登革热疫苗方面取得了重大进展,赛诺菲巴斯德公司的登卡夏疫苗是第一个获得许可批准使用的疫苗。利用各种方法,如重组蛋白、病毒载体和病毒样颗粒,提供了各种替代品,旨在成为更安全的登卡夏替代品,同时保持有效性。对登革热进行审查对于临床医生和卫生保健专业人员及时了解诊断、治疗方案和预防战略至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Complexities of Dengue Fever: Pathogenesis, Clinical Features and Management Strategies.

Complexities of Dengue Fever: Pathogenesis, Clinical Features and Management Strategies.

Complexities of Dengue Fever: Pathogenesis, Clinical Features and Management Strategies.

Dengue fever, transmitted through the bite of infected Aedes mosquitos, poses a significant global threat, particularly in the tropical and subtropical region. In this review, we aim to summarize the existent literature on dengue virus infection and to enlighten the reader on recent advances and knowledge. Dengue virus infection can cause a spectrum of clinical manifestations, ranging from asymptomatic or mild illness to more severe and potentially life-threatening complications. Pathogenesis of dengue is based on viral and host factors. Viral factors include NS1 antigen and genomic factors. Host factors include antibody dependent enhancement, anti-NS1 antibodies, cytokines, cross reactive T-Cell response, HLA allele variation and non-HLA mediated polymorphisms. The clinical picture of dengue is described on the basis of WHO 1997 and 2009 criteria. It is classified into dengue fever, dengue hemorrhagic fever (DHF), and dengue shock syndrome (DSS). Life-threatening complications can develop in severe cases, and this includes renal complications such as acute kidney injury (AKI) and hepatic complications such as hepatic dysfunction and in rare cases, fulminant hepatic failure. Neurological complications, cardiac complications and respiratory distress syndrome have also been reported. Treatment methods include targeting the dengue vector and Carica papaya, a natural remedy with antiviral properties. Additionally, the role of corticosteroids, intravenous immunoglobulins, and mast cell inhibitors has been explored in dengue treatment, aiming to reduce severity. Novel approaches involve drugs targeting dengue proteins and host factors necessary for the virus's life cycle, offering potential avenues for more targeted therapeutic interventions. In recent years, significant progress has been made in the development of vaccines against dengue, with Sanofi Pasteur's Dengvaxia being the first licensed vaccine approved for use. Utilizing various approaches such as recombinant proteins, viral vectors and viral like particles, various alternatives have been provided which aim to be safer substitutes to Dengvaxia while maintaining the effectiveness. A review on dengue is essential for clinicians and healthcare professionals to stay updated on diagnostics, treatment protocols and prevention strategies.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信